Infliximab Drug Monograph Research Paper Example | Topics and Well Written Essays - 1500 words

Infliximab Drug Monograph - Research Paper Example In the market, the drug is traded under the brand name of Remicade. The drug’s main manufacturing center is in United States of America. Infliximab Drug Monograph Infliximab is a drug which is used to treat patients who suffer from rheumatoid, Crohn’s diseases, ankylosing sponylitis, ulcerative colitis, and plaque psoriasis. The Infliximab drug can also be explained as an antibody drug which is used to treat chronic inflammatory diseases. It blocks the impact of necrosis factor alpha which is commonly labeled as (TNF alpha). Necrosis factor alpha is a substance manufactured by human cells, which plays a very crucial role in hiking inflammation in human body. Necrosis factor alpha is manufactured in the body immune system, hence Infliximab is used to reduce the effect of necrosis alpha factor in the body parts and most specifically. in the immune system. The generic name used for this drug is Infliximab while the brand name for the drug is Remicade. Patients with heart f ailure should not receive Infliximab unless tested by the doctor on their capability of sustaining the impact of the drug in the body. Additionally, patients with allergic reaction to Infliximab constitutes are also instructed not to use them (Frederic, 2010). Therapeutic Category The Infliximab therapeutic category is antirheumatic, GI anti-inflammatory (Frederic, 2010). Dosage The most effective dosage for infusion is 5mg/kg of Infliximab which should be administered and used for a period of 0-6 weeks. The patient should then be administered with another 5mg/kg for every eight weeks. The second dosage is administered in the situation where the patient is at moderate to severe infusion condition. This dosage applies to adult and pediatric patients only. In the situation where the patient does not respond to the dosage, he/she should be administered with a dosage of 10mg/kg. The required and most effective dosage for moderate to severe active rheumatoid arthritis is supposed to be 3 mg/kg for the initial 0-6 weeks which should be accompanied by another 3mg/kg for every eight weeks. In the situation where the patient does not respond completely to the drug, he/she should be instructed to take 10mg/kg of Infliximab drug. Alternatively, the doctor should ensure the treatment is conducted for every four weeks to enhance consistency. Other diseases such as ulcerative colitis, plaque psoriasis and psoriatic arthritis should be treated with 5mg/kg for 0-6 weeks which should be followed by5mg/kg for every eight weeks. The ankylosing is better treated by 5mg/kg of Infliximab for the first 0-6 weeks which should be accompanied by 5mg/kg for every 6 weeks. Children are strictly not recommended to use the infliximab drug. Indication Infliximab is used for treating and reducing the symptoms and signs of moderate to severe Crohn disease. The drug has also been confirmed as one of the best drug in treatment of active psoriatic arthritis among the adults and children who are a bove the age of six years. The joint inflammation of rheumatoid arthritis, ankylosing spondylitis, psoariatic arthritis among the juvenile are treated using the infliximab drug. The uveitis and sarcoidosis which do not respond positively to traditional therapies are also healed by this drug. The Infliximab drug is also one of the best in the treatment of pediatric patients who have moderate to severe active Crohn diseases. The drug is applied to the patients